Casi pharmaceuticals announces renewal of exclusive distribution agreement for evomela® in china

Rockville, md. and beijing, march 4, 2022 /prnewswire/ -- casi pharmaceuticals, inc. (nasdaq: casi), a u.s. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced today, that the company has entered into a renewal exclusive distribution agreement, whereby under the terms of the agreement, china resources pharmaceutical commercial group international trading co., ltd.
CASI Ratings Summary
CASI Quant Ranking